Andreas Maetzel Biography and Net Worth

Dr. Andreas Maetzel M.D. Ph.D. serves as Senior Vice President - Medical of the Company. Dr. Maetzel joined as our Senior Vice President of Medical in March 2017. Dr. Maetzel was most recently Vice President, Global Medical Affairs at BioCryst Pharmaceuticals from August 2014 to February 2017. Prior to that he was Vice President, Clinical Development & Regulatory Affairs at Cornerstone Therapeutics Inc from May 2013 to February 2014. From September 2011 to April 2013, Dr. Maetzel held a clinical development role at BioCryst. He previously held positions in health technology assessment strategy at Amgen and in strategy consulting. He is Visiting Scientist at Charité Hospital Berlin, and maintains an appointment as Adjunct Professor at Institute for Health Policy, Management & Evaluation, University of Toronto. Dr. Maetzel obtained both a Ph.D. and an M.Sc. in Clinical Epidemiology from the University of Toronto and a Dr. Med. at the University of Hannover, Germany.

What is Andreas Maetzel's net worth?: The estimated net worth of Andreas Maetzel is at least $118,983.60 as of April 29th, 2021. Dr. Maetzel owns 11,017 shares of KalVista Pharmaceuticals stock worth more than $118,984 as of April 26th. This net worth evaluation does not reflect any other assets that Dr. Maetzel may own. Learn More about Andreas Maetzel's net worth.
How do I contact Andreas Maetzel?: The corporate mailing address for Dr. Maetzel and other KalVista Pharmaceuticals executives is 55 Cambridge Parkway Suite 901E, CAMBRIDGE MA, 02142. KalVista Pharmaceuticals can also be reached via phone at 857-999-0075 and via email at [email protected]. Learn More on Andreas Maetzel's contact information.
Has Andreas Maetzel been buying or selling shares of KalVista Pharmaceuticals?: Andreas Maetzel has not been actively trading shares of KalVista Pharmaceuticals in the last ninety days. Most recently, Andreas Maetzel sold 88,030 shares of the business's stock in a transaction on Thursday, April 29th. The shares were sold at an average price of $25.28, for a transaction totalling $2,225,398.40. Following the completion of the sale, the senior vice president now directly owns 11,017 shares of the company's stock, valued at $278,509.76. Learn More on Andreas Maetzel's trading history.
Who are KalVista Pharmaceuticals' active insiders?: KalVista Pharmaceuticals' insider roster includes Thomas Crockett (CEO), Edward Feener (Insider), Andreas Maetzel (SVP), Michael Smith (VP), and Christopher Yea (Insider). Learn More on KalVista Pharmaceuticals' active insiders.
Are insiders buying or selling shares of KalVista Pharmaceuticals?: During the last year, KalVista Pharmaceuticals insiders bought shares 13 times. They purchased a total of 448,522 shares worth more than $5,806,280.30. During the last year, insiders at the specialty pharmaceutical company sold shares 13 times. They sold a total of 212,109 shares worth more than $2,650,351.15. The most recent insider tranaction occured on February, 20th when insider Edward P Feener sold 28,288 shares worth more than $398,012.16. Insiders at KalVista Pharmaceuticals own 12.3% of the company. Learn More about insider trades at KalVista Pharmaceuticals.
Information on this page was last updated on 2/20/2024.

Andreas Maetzel Insider Trading History at KalVista Pharmaceuticals

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
4/29/2021	Sell	88,030	$25.28	$2,225,398.40	11,017
4/27/2021	Sell	11,017	$25.79	$284,128.43	11,017
4/5/2019	Sell	5,000	$30.00	$150,000.00	5,000

Andreas Maetzel Buying and Selling Activity at KalVista Pharmaceuticals

KalVista Pharmaceuticals Company Overview

KalVista Pharmaceuticals, Inc., a clinical stage pharmaceutical company, engages in the discovery, development, and commercialization of small molecule protease inhibitors for diseases with unmet needs in the United States. The company's product portfolio comprises small molecule plasma kallikrein inhibitors targeting hereditary angioedema (HAE) and diabetic macular edema (DME); and oral plasma kallikrein inhibitors. Its products include sebetralstat, which is initiation of the Phase 3 KONFIDENT trial as a potential oral, on-demand therapy for HAE attacks; and Factor XIIa, an oral inhibitor program which is in preclinical stage targets an enzyme in HAE. The company is headquartered in Cambridge, Massachusetts.

Today's Range

Now: $10.80

$10.26

$10.80

50 Day Range

MA: $12.45

$10.35

$14.86

2 Week Range

Now: $10.80

$7.21

$16.88

Volume

87,503 shs

Average Volume

717,060 shs

Market Capitalization

$455.65 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.88

These AI trades triggered this morning (545% return)

From Prosper Trading Academy | Ad

If you think a market crash is possible in 2024, I don't know why you're not using this yet.

Click Here To Get Your Free Copy